HAII Secures Second Place in Prestigious KHIDI-Roche Diagnostics Day ‘New Impact Project,’ Eyes Global Expansion

In a remarkable achievement, HAII, a Seoul-based digital health innovator, secured second place at the KHIDI-Roche Diagnostics ‘New Impact Project.’ This prestigious event, known for spotlighting groundbreaking advancements in healthcare, recognized HAII for its pioneering work in digital biomarkers and AI-driven diagnostics.

The accolade underscores HAII’s cutting-edge technology, particularly in early detection and monitoring of neurodegenerative diseases. The company’s flagship product, Alzguard, leverages advanced AI to provide highly accurate dementia diagnostics, achieving an impressive 88% accuracy rate. This tool, which utilizes a combination of keystroke dynamics, eye-tracking, and voice biomarkers, has also received K-FDA clearance for further clinical trials, marking a significant milestone in digital health innovation.

HAII’s recent success is bolstered by a substantial Series B investment back in 2022, bringing the company’s total funding to $8 million. This influx of capital reflects strong investor confidence in HAII’s potential and will fuel the company’s ambitious expansion plans. As part of these plans, HAII has established a subsidiary office in Cambridge, MA in 2023, furthering its commitment to global growth and positioning itself within the vibrant ecosystem of digital health innovation in the United States.

What sets HAII apart is its extensive database of digital biomarkers, the largest in South Korea, encompassing over 700,000 data points. This comprehensive dataset is integral to enhancing the accuracy of HAII’s AI models, offering a robust foundation for its diagnostic tools. The company’s commitment to data-driven healthcare innovation positions it as a frontrunner in the digital health sector.

Moreover, HAII has achieved significant regulatory milestones, including securing K-FDA approvals, which pave the way for broader clinical applications. This progress not only solidifies HAII’s standing in South Korea but also opens doors for international market expansion, bringing cutting-edge healthcare solutions to a global audience.

As HAII continues to innovate and expand, its role in transforming digital health is becoming increasingly prominent. The company’s recent accolades and strategic growth initiatives underscore its potential to revolutionize the diagnosis and treatment of neurodegenerative diseases worldwide. For more insights into HAII’s latest developments and future plans, visit their official website.

Also Read:

• Taiwan’s BBTruck Aims for Global Expansion with $6.5 Million Pre-Series A Funding
• Growsari Secures US$5M Investment to Empower 1.3M Sari-Sari Stores Across the Philippines
• AsiaTechDaily Names Victor Chua as Investor of the Month for August 2024
• Vietnam and Singapore Sign MoU to Boost Stock Exchange Collaboration
• Japanese Medtech Giant Terumo Establishes $75M Venture Capital Fund